TNFRSF17 and plasma cell myeloma: Based on the apparent role of BCMA in MM pathogenesis, and the limited reported expression on normal tissues, we set out to validate the expression of BCMA in MM and normal tissues followed by generation of a highly potent, and selective BCMA-targeting CAR for adoptive T-cell therapy in myeloma.